Sysvax

Sysvax is a private China-linked biotechnology company focused on antibody drugs and vaccines for infectious diseases and cancer. Publicly available descriptions indicate that the company operates R&D activities in Beijing and has had manufacturing facilities in Zhongshan, with work spanning recombinant protein vaccines, nanobody therapeutics, and related biologics technologies. During the COVID-19 period, Sysvax was described as developing a recombinant protein vaccine and a nanobody therapeutic, while also leveraging nanobody engineering to improve half-life and antiviral activity. Patent activity and scientific affiliations suggest ongoing capabilities in SARS-CoV-2-targeting nanobody and vaccine research. Overall, the company appears to be an early-stage biotech centered on infectious disease biologics discovery, translational research, and industrialization in China.